Dr. Michael Masterst
Doctor
Molecular Tumorbiology
University of Munster
Germany
Biography
1979-1985-Studies and Diploma in Chemistry, Munich, 1989-Dr. rer nat. in Biochemistry - LMU Munich (Mentor. Prof. Winnacker), 1989-92-Postdoc with Prof. Dr. RG Roeder, Rockefeller University, New York, 1989-91, 1992-DFG fellowship, Winston fellowship, 1992-97-Independent Group Leader, Gene Center, LMU Munich, 1997-Habilitation in Biochemistry, 1997-98-Interim Professorship Biochemistry, LMU Munich, 1997-Offer professorship of Biochemistry, University Erlangen, 1998-2007-Section head of Gene expression, Helmholtz-Center Munich, Since 1/2008-Chair Institute of Molecular Tumor Biology, WWU Münster
Research Interest
Molecular Tumorbiology
Publications
-
Vojnic E, Mourão A, Seizl M, Simon B, Meisterernst M, et al. (2015) Structure and VP16 binding of the mediator Med25 activator interaction domain. Nat Struct Mol Biol 18: 404-409.
-
Kelso TW, Baumgart K, Eickhoff J, Albert T, Meisterernst M, et al. (2014) Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells. Mol Cell Biol 34: 3675-3688.
-
Albert TK, Rigault C, Eickhoff J, Baumgart K, Meisterernst M et al. (2014) Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor. Br J Pharmacol 171: 55-68.
-
Lopez C, Covarrubias A, Montecino M, Albert T, Slebe JC, et al. (2015) Wnt / beta-catenin signaling pathway does not regulate c-myc gene expression in 42GPA9 (mouse adult Sertoli) cellline FEBS J 282: 73-73.
-
Albert TK, Antrecht C, Kremmer E, Meisterernst M (2016) The establishment of a hyperactive structure Allows the tumor suppressor protein p53 to function through P-TEFb under Limited CDK9 kinase inhibition. PLoS ONE 11: e0146648.
